Q3 2025 Elevance Health Inc Earnings Call Transcript
Key Points
- Elevance Health Inc (ELV) reported a solid third quarter performance with a benefit expense ratio in line with expectations.
- The company reaffirmed its 2025 adjusted EPS of approximately $30, indicating confidence in its financial outlook.
- Elevance Health Inc (ELV) is making significant investments in AI and digital tools to enhance member and provider experiences, which are expected to drive long-term growth.
- The company is seeing strong growth in its Carelon segment, with Carelon Rx revenue growing 20% year over year.
- Elevance Health Inc (ELV) has maintained strong client retention in its commercial health benefits business, reflecting trust in its integrated medical pharmacy model and advocacy solutions.
- Elevance Health Inc (ELV) expects a decline of at least 125 basis points in Medicaid margins in 2026 due to elevated acuity and utilization trends.
- The company anticipates a high single-digit decline in full-year operating margin for its ACA market due to higher population mobility and rising unit costs.
- Elevance Health Inc (ELV) is facing challenges with Medicaid performance, which is expected to be modestly negative for the full year 2025.
- The anticipated expiration of enhanced subsidies could significantly impact membership in 2026, posing a risk to the ACA market.
- Elevance Health Inc (ELV) is planning for several hundred million dollars of incremental investments in 2026, which may impact near-term expense leverage.
Ladies and gentlemen, thank you for standing by, and welcome to the Elevance Health third quarter earnings conference call. (Operator Instructions) As a reminder, today's conference is being recorded. I would now like to turn the conference over to the company's management. Please go ahead.
Good morning, and welcome to Elevance Health' Third Quarter 2025 Earnings Conference Call. My name is Nathan Rich, Vice President of Investor Relations. With us this morning on the earnings call are Gail Boudreaux, President and CEO; Mark Kaye, our CFO; Pete Haytaian, President of Carillon.
Morgan Kendrick, President of our Commercial Health Benefits business; and Felicia Norwood, President of our Government Health Benefits business. Gail will begin the call with a discussion of our third quarter performance, our planning assumptions for 2026 and the progress we've made against our strategic initiatives.
Mark will then discuss our financial results and outlook in greater detail. After
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
